MedTrace Logo

Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow

NCT00248703 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1128

Last updated 2022-04-22

No results posted yet for this study

Summary

The purpose of this study is to identify patients with persisting tumor cells after standard epirubicin-containing treatment to test a non-cross resistant chemotherapy regimen (docetaxel) for these patients, and to explore the analysis of disseminated tumor cells in bone marrow as a surrogate marker for clinical outcome.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel 100 mg/m2 3 qw x 6

Sponsors & Collaborators

  • University of Tromso

    collaborator OTHER

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Sorlandet Hospital HF

    collaborator OTHER_GOV

  • Sykehuset Innlandet HF

    collaborator OTHER

  • Ullevaal University Hospital

    collaborator OTHER

  • Sykehuset i Vestfold HF

    collaborator OTHER

  • Sykehuset Ostfold

    collaborator OTHER

  • Alesund Hospital

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Bjørn Naume, MD, PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2012-11-30
Completion
2022-04-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00248703 on ClinicalTrials.gov